PVR and prostate cancer: In support of our proposition, a reanalysis of AR binding with an AR ChIP-seq dataset containing both normal and tumor samples of prostate cancer revealed that AR binds only to the PVR enhancer region in the prostate tumor samples but not in the normal prostate tissue (Pomerantz et al., 2015).